Overview

A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).
Phase:
Phase 2
Details
Lead Sponsor:
Almirall, S.A.